Sparrow Pharmaceuticals (Series B)
Funding Details
Awarder
Inbox
Date Award
September 24, 2025
Vertical
Pharmaceuticals
Funding Amount
$95,000,000
Company Info
Market
Cardiometabolic therapeutics
Location
Portland, Oregon, USA
Coinvestors
Forbion Capital Partners, OrbiMed Advisors, RA Capital Management, RiverVest Venture Partners, US Venture Partners
Company Description

Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company delivering improved outcomes for patients who struggle to control diabetes and related metabolic conditions with current options. The company's lead candidate, clofutriben, is a once-daily, oral HSD-1 inhibitor in development for the millions of patients with type 2 diabetes and elevated cortisol.

Links